

PRINTER RUSH (PTO ASSISTANCE)

Application : 09/542,520 Examiner : Kunz GAU : 1647
From: NPB Location: (IDC) FMF FDC Date: 11/10/04

Tracking #: 05936713 Week Date: 4/19/04

IFWLE)

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449	_____	<input checked="" type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS	_____	<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM	_____	<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW	_____	<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW	_____	<input checked="" type="checkbox"/> Other <i>Drawing Sheets</i>
<input type="checkbox"/> DRW	_____	
<input type="checkbox"/> OATH	_____	
<input type="checkbox"/> 312	_____	
<input type="checkbox"/> SPEC	_____	

[RUSH] MESSAGE:

① please verify relationship of continuing data Serial NO. 03/942596. bib sheet shows "CONTINUATION", text reads "CONTINUATION IN PART". (Palm cannot be updated - error message) - see attached.

Thank you

[XRUSH] RESPONSE:

INITIALS:

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.

REV 10/04



UNITED STATES PATENT AND TRADEMARK OFFICE

FILE COPY

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov


Bib Data Sheet

SERIAL NUMBER 09/542,520	FILING DATE 04/03/2000 RULE -	CLASS 530	GROUP ART UNIT 1646	ATTORNEY DOCKET NO. 7969-076-999
APPLICANTS W. James Jackson, Marriottsville, MD ; John L. Pace, Germantown, MD ;				
** CONTINUING DATA ***** THIS APPLICATION IS A CON OF PCT/US98/20737 10/01/1998 WHICH IS A CON OF 08/942,596 10/02/1997 <i>10-16-02</i>				
** FOREIGN APPLICATIONS ***** <i>none</i>				
IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 06/16/2000				
Foreign Priority claimed <input type="checkbox"/> yes <input checked="" type="checkbox"/> no 35 USC 119 (a-d) conditions <input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance Verified and Acknowledged <i>[Signature]</i> Examiner's Signature Initials		STATE OR COUNTRY MD	SHEETS DRAWING 11	TOTAL CLAIMS 61
INDEPENDENT CLAIMS 6				
ADDRESS 20583				
TITLE Chlamydia protein, gene sequence and uses thereof				
FILING FEE RECEIVED 2160	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit	

B1 This application is a continuation of PCT/US98/20737 filed October 1, 1998 which is a continuation-in-part of U.S. Patent Application No. 08/942,596 filed October 2, 1997.

IN THE CLAIMS:

Please cancel non-elected claims 1, 20, 23-31 and 38-41 without prejudice.

Please amend 21, 32, 33, 35-37 to read as set forth below:

B1' 21. (Once Amended) A method of producing an immune response in an animal comprising administering to said animal an effective amount of an antigenic composition comprising an isolated *Chlamydia* species high molecular weight (HMW) protein wherein the apparent molecular weight is about 105-115 kDa, as determined by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE), wherein the *Chlamydia* species is *Chlamydia trachomatis*, *Chlamydia pecorum*, or *Chlamydia pneumoniae*, or an analogue of the HMW protein wherein the analogue has an apparent molecular weight of about 105-115 kDa, as determined by SDS-PAGE and is recognizable by an antibody that specifically binds to a peptide comprising an amino acid sequence of SEQ ID No. 2, 15 or 16.

B2 32. (Once Amended) A method of preventing, treating or ameliorating a disorder related to *Chlamydia* in a host in need thereof comprising administering to a host, an effective amount of a pharmaceutical composition or vaccine composition comprising an isolated *Chlamydia* species high molecular weight (HMW) protein wherein the apparent molecular weight is about 105-115 kDa, as determined by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE), wherein the *Chlamydia* species is *Chlamydia trachomatis*, *Chlamydia pecorum*, or *Chlamydia pneumoniae*, or an analogue of the HMW protein wherein the analogue has an apparent molecular weight of about 105-115 kDa, as determined by SDS-PAGE and is recognizable by an antibody that specifically binds to a peptide comprising an amino acid sequence of SEQ ID No. 2, 15 or 16 or a fragment of said HMW wherein the fragment is recognizable by an antibody that specifically binds to a peptide comprising an amino acid sequence of SEQ ID No. 2, 15 or 16 or a recombinant protein comprising a *Chlamydia* protein and a leader sequence, wherein the apparent